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Membrane fusionThe membrane-proximal external region (MPER) of gp41 is considered as a prime target for the induction of
neutralizing antibodies, since it contains the epitopes for three broadly neutralizing antibodies (2F5, 4E10
and Z13). Here we present a novel gp41 construct (HA-gp41) comprising gp41 HR2 and MPER fused to two
triple-stranded coiled-coil domains at both ends. HA-gp41 is trimeric, has a high helical content in solution
and forms rod-like structures as revealed by negative staining electron microscopy. Immunization of rabbits
with HA-gp41 induced antibodies directed against MPER, which failed to exert signiﬁcant neutralization
capacity against envelopes from primary isolates. Thus trimerisation of MPER regions does not sufﬁce to
induce a potent neutralizing antibody response speciﬁc for conserved regions within gp41.Introduction
Amajor challenge in HIV-1 vaccine research remains to identify an
immunogen that has the capacity to induce high titers of broadly
neutralizing antibodies. Highlighting the problem, to date only a very
limited number of envelope glycoprotein (Env) speciﬁc antibodies
have been identiﬁed that are broadly cross-reactive (Burton et al.,
2004). Monoclonal antibody (mAb) b12 recognizes the conserved CD4
binding site on gp120 (Burton et al., 1994), mAb 2G12 binds
carbohydrates on gp120 (Trkola et al., 1996), and mAbs 2F5, 4E10
and Z13 are directed against highly conserved adjacent epitopes in the
membrane-proximal external region (MPER) of the Env glycoprotein
subunit gp41 (Muster et al., 1993; Nelson et al., 2007; Stiegler et al.,
2001; Zwick et al., 2001). Although a variety of gp41 antigens have
been studied as immunogens (Lenz et al., 2005; Mantis et al., 2001;
Qiao et al., 2005) and much interest and resources have been invested
to develop immunogens that are capable of inducing 2F5- and/or
4E10-like immune responses (Karlsson Hedestam et al., 2008; Zwick,
2005), no such activities have yet been reported (Qiao et al., 2005). In
contrast, phage display technologies have been used successfully toraction, UMI 3265 UJF-EMBL-
ance. Fax: +33 476 209400.
orn).
ll rights reserved.isolate gp41 speciﬁc antibodies with limited neutralization activity
(Gustchina et al., 2007; Louis et al., 2005; Luftig et al., 2006; Nelson et
al., 2007), and patient sera contain antibodies overlapping with and
potentially masking gp41 MPER (Alam et al., 2008).
Monoclonal antibody (mAb) 2F5 recognizes a linear sequence that
adopts an extended conformation containing a short beta turn (Ofek
et al., 2004) while the adjacent epitope of mAb 4E10 forms a helical
structure in complex with 4E10 (Cardoso et al., 2005) and in solution
(Schibli et al. 2001; Sun et al., 2008). Since linear peptides comprising
both epitopes are immunogenic but do not induce neutralizing
antibodies several strategies to constrain the recognized antigen
conformation have been developed with little success in generating
MPER-speciﬁc neutralizing antibody responses (Barbato et al., 2003;
Brunel et al., 2006; Cardoso et al., 2007; Law et al., 2007; McGaughey
et al., 2003). Both mAbs 2F5 and 4E10 contain long CDR3 regions,
which were shown to be important for neutralization in case of 2F5
(Zwick et al., 2004). Furthermore, both mAbs have been suggested to
interact with lipids and may thus recognize self-antigens (Alam et al.,
2007; Brown et al., 2007; Haynes et al., 2005a; Sanchez-Martinez
et al., 2006a; Sanchez-Martinez et al., 2006b); this notion was further
reinforced by the potential embedding of the 4E10 epitope in a lipid
bilayer (Sun et al., 2008). However, some controversy about this mode
of action prevails (Scherer et al., 2007) consistent with failures to
induce neutralizing antibody responses by proteoliposomes contain-
ing membrane anchored gp41 including MPER and helical region 2
Fig. 1. HA-gp41 forms trimers. (A) Schematic representation of gp41 and HA-gp41. (B)
Size exclusion chromatography of HA-gp41 shows that HA-gp41 elutes as a larger
complex ∼100 kDa. (C) Chemical cross-linking reveals trimer formation; two new
bands migrating at ∼40 and 60 kDa appear upon incubationwith increasing amounts of
EGS (0, 1, 2, 5 and 10 mM). (D) Native gel electrophoresis of HA-gp41. Lane 1 HA-gp41;
HA-gp41 incubated with 10% (lane 2), 25% (lane 3) and 50% (lane 4) Freund's adjuvant.
222 A. Hinz et al. / Virology 390 (2009) 221–227(HR2) inmice (Lenz et al., 2005), rabbits andmacaques (Wagner et al.,
2007; Quendler et al., unpublished results).
Since gp41 can at least adopt three conformations, a native one
within Env trimers, a postulated fusion-intermediate (pre-hairpin)
and a post-fusion conformation (Bures et al., 2000; Harrison, 2005;
Lamb and Jardetzky, 2007; Weissenhorn et al. 2007), the question
remains what kind of Env antigen mAbs 2F5 and 4E10 recognize;
native Env versus a fusion-intermediate conformation of gp41
(de Rosny et al., 2004; Finnegan et al., 2002; Zwick et al., 2001).
Notably Frey and colleagues have reported that bothmAbs do not bind
native soluble Env trimers but interact with a potential fusion-
intermediate conformation (Frey et al., 2008) consistent with
proposed epitope exposure and MPER recognition by both mAbs
during the membrane fusion process (Dimitrov et al., 2007).
Here we present a novel gp41 antigen, HA-gp41, that contains the
MPER and HR2 regions ﬂanked by two trimerization domains, an N-
terminal fragment of inﬂuenza virus hemagglutinin subunit 2 (HA2)
(Mantis et al., 2001), and a C-terminal trimeric GCN4 variant (Harbury
et al., 1993; Weissenhorn et al., 1997a). We show that HA-gp41 forms
elongated, rod-shaped andmostly helical trimers in solution that bind
both mAbs 2F5 and 4E10 with nanomolar afﬁnities. Immunization of
rabbits with HA-gp41 induced high titers of HA-gp41 speciﬁc
antibodies that recognized MPER peptides but failed to exert
signiﬁcant neutralization activity.
Results
Antigen characterization
Chimeric HA-gp41, composed of an N-terminal triple-stranded
coiled-coil region derived from the inﬂuenza virus hemagglutinin
subunit 2 (HA2), gp41 HR2 andMPER, and a trimeric GCN4 coiled-coil
region (Fig. 1A) eluted from a preparative Sephacryl 200 gel ﬁltration
column at a molecular weight of ∼100 kDa, between the elution
positions of two marker proteins of 160 kDa and 66 kDa (Fig. 1B).
Consistent with the presence of two trimerization domains, chemical
cross-linkingofHA-gp41 revealed the appearance of twonewbands on
an SDS-PAGE upon incubation with increasing amounts of EGS,
migrating at ∼40 kDa and ∼60 kDa, respectively (Fig. 1C). Circular
dichroism demonstrated an overall α-helical content (Fig. 2A), which
was estimated to be∼80% based on the analysis with K2D (www.cryst.
bbk.ac.uk), and a temperature dependent unfolding at∼55 °C (Fig. 2B).
Further analysis by negative staining electronmicroscopy showed rod-
like structures containing short ﬂexible extensions (Fig. 2C). Two-
dimensional averaging revealed an approximate length of 115 Å+/
−10Å (Fig. 2D) and a thickness of 45+/−5Å,with one end showing the
trimer symmetry of the particle in the top view (Fig. 2E). The side view of
the averaged particle indicated further that one end of the particle is well
deﬁned, while the other end appeared to be smeared out (Fig. 2D). Thus a
ﬂexibly linked regionof oneendmighthavebeen lost due to the averaging
procedure. Since the triple-stranded coiled-coil structures of HA2 and
GCN4 used in the fusion protein account for ∼100 Å, gp41 contributes at
least 25 Å, consistent with a larger gp41 contribution of ∼45 Å present in
the gp41-inter construct (Frey et al., 2008).
The binding constants of Fabs derived from mAbs 2F5 and 4E10 to
HA-gp41 were determined by surface plasmon resonance (SPR)
(Figs. 3A and B). The association rates (ka) were 2.96×105 M–1s–1
for the 2F5 Fab and 1.24×105 M–1s–1 for the 4E10 Fab, and the dis-
sociation rate (kd) was 6× faster for 4E10 (1.07×10−4 s–1) than for 2F5
(6.62×10−4 s–1). Accordingly the afﬁnity (KD) of 2F5was elevated bya
factor of 10 (0.36 nM) when compared to 4E10 (5.34 nM) (Table 1).
Immunogenicity of HA-gp41
Five rabbits were immunized four times with HA-gp41 and
Freund's complete adjuvant at days 0, 21, 42 and 63, followed by aﬁnal bleed at day 77. Native gel electrophoresis of HA-gp41 alone
revealed a single band (Fig. 1D); this pattern did not change upon
incubation with increasing concentrations of Freund's adjuvant
suggesting that the trimeric structure of HA-gp41 was still intact in
the presence of Freund's adjuvant. Reciprocal titers of the sera against
the antigen HA-gp41 were determined by ELISA and varied between
1:830,677 and 1:147,662 (Table 2). HA-gp41 speciﬁc IgG antibodies
were puriﬁed from sera by afﬁnity chromatography and both serum
and IgGs were employed to detect neutralization activity. All sera and
puriﬁed IgGs were found to be negative in a TZM-b1 assay, using Tier 1
and Tier 2 viruses. In contrast, when sera and afﬁnity puriﬁed IgGs
were tested in a PBMC assay, signiﬁcant neutralization of a few PBMC-
grown B-clade primary isolates such as Tier 2 viruses PVO.4, 6535.3
and QH0692.42 and Tier 1 SF162.LS was observed. However, since the
samples turned out to be contaminated with endotoxin the sig-
niﬁcance of neutralization is highly questionable (D. Monteﬁori,
unpublished results) and most likely due to the presence of
endotoxins in the samples tested. In order to better evaluate potential
neutralization, a third assay format was used that employs the low
CCR5-expressing cell line 5.25.EGFP.Luc.M7 that was suggested to be
more sensitive for certain antibodies including MPER-speciﬁc neu-
tralizing antibodies (Choudhry et al., 2006). However, no signiﬁcant
neutralization of the sera against three clade B Tier 1 viruses could be
observed. Thus the conclusion from the current study is that HA-gp41
did not induce neutralizing activity.
Thepuriﬁed IgGswere further tested for theirwesternblot reactivity
against the T-20 peptide containing a part of HR2 and the 2F5 epitope as
well as anMPER peptide containing only the 2F5 and the 4E10 epitopes
(Fig. 4A). The western blot revealed that both peptides are recognized
Fig. 3. Both mAbs 2F5 and 4E10 bind HA-gp41 with high afﬁnity. HA-gp41 was
immobilized on a Ni-NTA chip and sensorgrams are shown for (A) the 2F5 Fab (the
concentrations of the analyte were 100, 50, and 10 nM), and (B) the 4E10 Fab
(concentrations of the analyte were 100, 50, and 10 nM). Binding kinetics were
evaluated with a 1:1 Langmuir model and the ﬁts are shown. The rate and binding
constants are summarized in Table 1.
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rabbit sera; only rabbit serum #2 showed rather weak reactivity with
the peptides (Fig. 4B). This indicated that MPER was immunogenic in
the context of the trimer construct. To further evaluate the presence of
antibodies that cross-react with the 2F5 and 4E10 epitopes we
performed a competition ELISA. HA-gp41 was directly coated on the
plates and detection of biotinylated 2F5 or 4E10 was competed with
increasing amounts of serum IgG from rabbit # 4 and # 5. This revealed
that both sera contained antibodieswhich interferedwith 2F5 and 4E10
binding (Fig. 4C) thus indicating the presence of antibodies that at least
overlap with either the 2F5 or the 4E10 epitopes.
Discussion
Broadly neutralizing antibodies directed against the conserved
gp41 MPER are thought to be a key element of a potential HIV-1Fig. 2. Circular dichroism and negative staining electron microscopy reveal rod-shaped
helical structures. (A) Circular dichroism analysis of HA-gp41 and temperature
dependent unfolding (B) of HA-gp41 recorded at 220 nm. (C) Electron micrograph of
HA-gp41 negatively stained by using sodium silicotungstate at pH 9.0. The arrows
indicate the rod-like structure of the protein and the asterisks an extra part that seems
to be ﬂexibly linked to the rod. (D) Selected side views of the rod-like structure. The
average structure resulting from 180 selected side views is shown on the right. (E)
Selected top views of the rod-like structure. The average structure resulting from 40 top
views is shown on the right showing a triangular shape.
Fig. 4. Epitope recognition by the rabbit sera obtained upon HA-gp41 immunization.
Table 1
Fabs of the neutralizing antibodies 2F5 and 4E10 interact with HA-gp41 with high
afﬁnity as determined by SPR.
ka (M−1s−1) kd (s−1) KD (nM)
2F5 Fab (2.96±0.42) E5 (1.07±0.02) E−4 0.36±0.05
4E10 Fab (1.24±0.74) E5 (6.62±3.66) E−4 5.34±3.19
224 A. Hinz et al. / Virology 390 (2009) 221–227vaccine (Burton et al., 2004; Karlsson Hedestam et al., 2008; Walker
and Burton, 2008) since three broadly neutralizing antibodies 2F5,
4E10 and Z13 recognize linear epitopes within MPER (Muster et al.,
1993; Nelson et al., 2007; Parker et al., 2001; Stiegler et al., 2001;
Zwick et al., 2001). Although themain structural principles for epitope
recognition have been elucidated (Cardoso et al., 2007; Cardoso et al.,
2005; Ofek et al., 2004), the nature of the antigen, which can elicit
such antibody speciﬁcities, is still elusive. Multiple approaches to
generate antigens that present both epitopes as peptides, constrained
peptides or within protein scaffolds have failed to produce neutraliz-
ing antibodies in animal models (reviewed in Montero et al. (2008)).
Anumberof studies suggested that2F5and4E10 react poorly if at all
with native envelope trimers (Binley et al., 2003; Cavacini et al., 2002;
Zwick et al., 2001) and might only interact with an intermediate
conformation of gp41 that is induced by receptor binding (de Rosny
et al., 2004; Frey et al., 2008). We thus set out to deﬁne a trimeric
fusion-intermediate conformation of gp41 that could represent the
native target for mAbs 2F5 and 4E10. This intermediate conformation,
HA-gp41, contains MPER and HR2 fused to two triple-stranded coiled-
coil regions at both ends and follows a similar principle as applied in
case of gp41-inter, published by Frey et al., which contains MPER, HR2
and the cystein-loop region constrained between two triple-stranded
coiled-coil regions (Frey et al., 2008). HA-gp41 interacts with Fabs
derived frommAbs 2F5 and 4E10with high nanomolar afﬁnities similar
to those reported for gp41-inter (Frey et al., 2008). Both HA-gp41 and
gp41-inter have similar helical contents indicating that at least parts of
HR2 and/orMPERmust adoptα-helical secondary structures. HA-gp41
and gp41-inter fold into elongated rod-like structures with a similar
length contribution of the gp41 part; ∼25 Å in case of HA-gp41 versus
45Å in case of gp41-inter. Thedifference in length is probably due to the
fact that gp41-inter contains the Cys-loop region and thus ∼100 gp41-
speciﬁc amino acids (Frey et al., 2008) while HA-gp41 contains only 60
gp41-specifc amino acids (Fig. 1A). However albeit their slight
differences in design, both structures, gp41-inter (Frey et al., 2008)
and HA-gp41 might resemble the proposed fusion-intermediate
conformation of gp41 (Weissenhorn et al., 1997b). It is also notable
that HA-gp41 does not contain the immunodominant region (cluster I)
preceding the Cys-loop region,which inducesmost of the gp41-speciﬁc
antibodies in patient sera (Gnann et al. 1987; Xu et al., 1991).
HA-gp41 was shown to be immunogenic and produced gp41-
speciﬁc antibodies, which recognized epitopes overlapping with 2F5
and 4E10 epitopes as judged bywestern blot analysis and competition
ELISA. However, the sera and puriﬁed HA-gp41-speciﬁc antibodies
showed no signiﬁcant neutralization activity against Tier 1 and Tier 2
clade B isolates in the TZM-b1 reporter cell line assay (Monteﬁori,
2005). We next determined signiﬁcant neutralization activity of the
sera and puriﬁed HA-gp41-speciﬁc antibodies using a PBMC based
assay format. We reasoned that detection of neutralization might be
due to the differences between both assays (Brown et al., 2008;
Polonis et al., 2008); the PBMC assay probably reﬂects a slower kinetic
of infection based on lower co-receptor surface concentrationsTable 2
Titers of HA-gp41 IgG were determined by ELISA.
#1 #2 #3 #4 #5
HA-gp41 nt 209,036 147,662 404,868 830,677
The titer of rabbit serum #1 could not be determined.(Choudhry et al., 2006). This might be more favourable to detect
neutralizing MPER-speciﬁc antibodies which act during the con-
formational changes leading to membrane fusion. However, later on
during the course of the study all samples (sera and puriﬁed HA-gp41-
speciﬁc antibodies) were tested positive for the presence of
endotoxins. Thus, because of the proven effect of endotoxins on the
outcome of PBMC based neutralization (Verani et al., 1997), we
consider the current neutralization results as negative unless proven
differently with endotoxin-free sera. The employment of the low
CCR5-expressing cell line 5.25.EGFP.Luc.M7 in a luciferase assay
(Monteﬁori, 2004) conﬁrmed further that no signiﬁcant neutraliza-
tion activity could be detected in the sera induced by HA-gp41
immunization.
The failure to generate neutralizing antibodies targeting the MPER
employing HA-gp41 might be due to the lack of lipid determinants
that have been suggested to be important for 2F5 and 4E10
neutralization via their CDR3 regions, which are only partially
employed for epitope binding (Cardoso et al., 2005; Ofek et al.,
2004). Due to their close binding mode to the membrane, the CDRs
have been implicated inmembrane interaction (Grundner et al., 2002;
Haynes et al., 2005a; Ofek et al., 2004; Sanchez-Martinez et al.,
2006a). Based on this hypothesis the problem to induce 2F5 and 4E10-
like antibody responses was attributed to the difﬁculty of inducing
autoreactive antibodies (Haynes et al., 2005b). Although the NMR
structure of the isolated peptide epitope indicated the potential of(A) Sequences of peptides T-20 and MPER used in the western blot analysis.
Hydrophobic (asterisk) and polar (circle) residues contacting either mAb 2F5 (black)
or 4E10 (blue) are indicated. (B) Western blot analysis of afﬁnity puriﬁed IgG. Staining
withmAb 2F5 reveals two bands corresponding to the T-20 andMPER peptides. Puriﬁed
IgGs were employed in 1:4 dilutions per lane. (C) Rabbit sera compete with 2F5 and
4E10 binding to HA-gp41 as detected by ELISA. The relative absorbance of labeled 2F5
and 4E10 are plotted against the serum dilution, indicating recovery of the signal at high
serum dilutions (squares 4E10 and circles 2F5 reactivities for two rabbit sera).
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membrane environment previously failed to produce neutralizing
antibodies in mice (Lenz et al., 2005), guinea pigs (Kim et al., 2007),
rabbits and macaques (Quendler, unpublished results). These results
thus argue against the potential positive effect of a lipidic environ-
ment for the elucidation of 2F5 and 4E10-like antibodies. Thus both
mAbs might not recognize self-antigens (Scherer et al., 2007).
HA-gp41 immunization produced antibodies speciﬁc for MPER,
which is consistent with the presence of such antibodies in patient
sera (Alam et al., 2008; Penn-Nicholson et al., 2008). These antibodies
either contribute to neutralization (Binley et al., 2008; Shen et al.,
2009; Sather et al., 2009) or are considered to be mostly non-
neutralizing and might mask MPER (Alam et al., 2008). However,
since we do not observe signiﬁcant neutralization, the epitopes
recognized by the seramight only overlap with that of 2F5 and 4E10 or
even m44 that was suggested to target HR2 with no requirements for
lipids (Zhang et al., 2008) without displaying the same ﬁne speciﬁcity.
Furthermore HA-gp41might induce preferentially antibodies masking
MPER, which could partially explain the failure to obtain signiﬁcant
neutralizing activity. In summary, our results suggest that the trimeric
conformation represented by HA-gp41 was not beneﬁcial to obtain
neutralization activity indicating that either MPER was not presented
in the correct trimer context or lacked important additional factors
such as a membrane environment. Finally, it is possible that Freund's
adjuvant might impede efﬁcient epitope exposure since it might
interfere with the hydrophobic nature of the epitopes targeted
although the trimer structure was most likely not affected by
incubation with Freund's adjuvant. It is thus necessary to determine
whether more efﬁcient immunization strategies can be employed
using HA-gp41 alone or in combination with a speciﬁc adjuvant or
prime-boost regimen to broaden the generation of neutralizing
antibodies by directing the immune response speciﬁcally towards
the MPER.
Material and methods
Protein expression and puriﬁcation
HA-gp41 is composed of the inﬂuenza virus hemagglutinin subunit
2 region (amino acids 372–417) followed by a linker composed of
amino acids Gly-Ser-Thr, the clade B HR2 and MPER regions (residues
629–683, HXB2c numbering) and a trimeric GCN4 isoleucine zipper
motif. The cDNA was cloned into pETM-11 (EMBL, Heidelberg) using
standard PCR techniques. HA-gp41 was expressed in Escherichia coli
Rosetta 2 (DE3). Cells were grown to an OD600 of 0.8 and induced with
0.5 mM IPTG at 37 °C. After 4 h cells were harvested by centrifugation
and lysed in buffer A (20 mM Tris pH 8, 100 mM NaCl). HA-gp41 from
the soluble fraction was puriﬁed on a Ni2+ afﬁnity column in buffer A
and eluted with 250 mM imidazole. A ﬁnal puriﬁcation step included
gel ﬁltration chromatography on a Sephacryl 200 HiPrep column (GE
Healthcare) in PBS.
Inclusion bodies of HA-gp41 were puriﬁed using standard
protocols. Brieﬂy, inclusion bodies were washed three times with
buffer A containing 0.5% Triton X-100, followed by a detergent-free
wash in buffer A, and solubilized in buffer B (50 mM acetate pH 4.5,
8 M guanidine). Inclusion bodies were stored at −80 °C at
concentrations between 20 and 30 mg/ml. HA-gp41 was refolded at
concentrations of 2 to 3 μM at 4 °C by rapid dilution into PBS buffer,
followed by overnight incubation. The refolded protein was further
puriﬁed as described above for the soluble fraction. The total yield of
soluble and refolded HA-gp41 is about 2 mg per liter E. coli culture.
Surface plasmon resonance
All experiments were performed in duplicate with a Biacore X
instrument (Biacore. Inc.) at 25 °C in buffer C (10 mM HEPES pH 7.4,150 mM NaCl, 50 μM EDTA, 0.05% Surfactant P20) at a ﬂow rate of
30 μl/min. HA-gp41 was immobilized on channel 2 of a Ni-NTA chip at
a concentration of 10 μg/ml for 2 min, channel 1 was used as control.
Fabs of 2F5 and 4E10 were passed over the chip surface at
concentrations of 100, 50, and 10 nM for 3 min, dissociation was
recorded for 15 min. Afterwards, the chip was regenerated with
0.35 M EDTA in buffer C for 1 min at a ﬂow rate of 50 μl/min and
100mMNaOH each, respectively, followed by recharging with 500 μM
NiCl2 in buffer C for 2 min at 30 μl/min. Binding kinetics were
evaluated using the BiaEvaluation software package (Biacore).
Circular dichroism
Circular dichroism (CD) measurements were carried out on a Jasco
J-810 spectro-polarimeter (JascoLtd, Tokyo, Japan) equipped with a
temperature control. Spectra were recorded in buffer D (10 mM
sodium phosphate pH 7.4, 100 mM NaF) at a protein concentration of
8 μM. Thermal unfolding of HA-gp41 was monitored by recording the
mean residue ellipticity at 220 nm as a function of the temperature.
The resulting spectra were analyzed with the DiChroWeb software
package available at www.cryst.bbk.ac.uk.
Electron microscopy
Samples were applied to the clean side of carbon onmica (carbon/
mica interface) and negatively stained with 1% sodium silicotungstate
pH 9.0. A grid was placed on top of the carbon ﬁlm, and subsequently
air-dried. Micrographs were taken under low-dose conditions with a
Jeol 1200-EX II microscope at 100 kV and a calibrated magniﬁcation of
39,750 times (based on the helical pitch of Tobacco Mosaic Virus).
Selected negatives were digitized on a Zeiss scanner (Photoscan TD)
with a pixel size of 7 μm (1.75 Å at the sample scale).
Image processing and model representation
2D averaging of particles was performed as follows: A total of 180
side views and 40 top views were selected using the X3d program
(Conway and Steven, 1999) and averaged together after cross-
correlation using SPIDER (Frank et al., 1996). The average size of the
rods was determined to be 115 Å+/−10 Å×45+/−5 Å. The
signiﬁcant variation of the rod length is most likely due to the
averaging procedure and the overall shape of the rods. The images
show some ends of the rod out of the plane. The averaging procedure
thus produced an image where one end of the rod is well deﬁned
while the other one appears smeared out indicating that parts of the
end were averaged out.
Chemical cross-linking and native gel electrophoresis
Samples from gel ﬁltrationwere treatedwith 1, 2, 5 and 10mMEGS
(ethylen-glycol bis(succinimidyl-succinate)) for 15 min at room
temperature. The reaction was quenched with 50 mM Tris pH 8.0
and samples were analyzed by SDS-PAGE. 20 μg of HA-gp41 was
incubated with Freund's complete adjuvants at 10% (v/v), 25% (v/v)
and 50% (v/v) for 30 min and separated on a 12% native
polyacrylamide gel. Bands were visualized by Coomassie brilliant
blue staining.
Immunization
Five New Zealand rabbits of mixed sexes (3 females and 2 males)
were immunized 4 times with 20−30 μg antigen at days 0, 21, 42 and
63. Brieﬂy, equal volumes of HA-gp41 and Freund's complete
adjuvants (280 μL each) were mixed and the resulting suspension
was injected subcutaneously and intramuscularly (2 times each per
rabbit). Pre-immunization samples of the blood serum (1 ml) were
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after the removal of food. The terminal bleeding was done on day 77.
Sera were stored at −20 °C until further use.
Puriﬁcation of gp41-speciﬁc antibodies
5 mg HA-gp41 was coupled to 1 g CNBr-activated Sepharose (GE
Healthcare) following manufacturer's instructions. Rabbit sera were
diluted one time with PBS and passed over the HA-gp41 afﬁnity
column. HA-gp41 speciﬁc antibodies were eluted with 50 mM glycine
pH 2.5 into a solution containing 1 M Tris HCl pH 9. Antibodies were
dialyzed against PBS, sterile ﬁltered and stored at 4 °C until further
use.
Neutralization assay
Serum and puriﬁed IgG samples were tested against ﬁve Tier 1
viruses (clade B: SF162.LS, BAL.26, SS1196.1, DJ263; clade C
MW965.26) and eight Tier 2 viruses (clade B: QHO692.42,
SC422661.8, PVO.4, 6535.3, AC10.029, RHPA4259.7, TRO.11 and
TRO4156.18) using the TZM-b1-assay (Monteﬁori, 2009). A second
assay included the determination of virus neutralization as a function
of reductions in p24 Gag antigen synthesis by using peripheral blood
mononuclear cell (PBMC)-grown viruses (SF162.LS, 6535.3,
QH0692.42 and PVO.4) and phytohemagglutinin (PHA)-stimulated
PBMC as targets for infection as described (Bures et al., 2000). Serum
endotoxin levels were determined using an ELISA assay and ranged
from 500 to N50,000 EU/ml. A third neutralization assay was
performed to establish potential neutralization by using 3 clade B
viruses (SF162, Bal, WEAU3-3) in the low CCR5-expressing cell line
5.25.EGFP.Luc.M7 (Monteﬁori, 2004).
Western blot analysis
5 μg of T-20 and MPER peptides, respectively, were separated on a
16% Tricine SDS-PAGE and transferred onto a nitrocellulosemembrane
for western blot analysis. 10 μg of afﬁnity puriﬁed rabbit IgG and 10 μg
of 2F5 were used for incubation and detection of peptides as shown in
the ﬁrst two lanes. The afﬁnity puriﬁed rabbit IgGs were then stepwise
diluted 1:4 per lane, thus using ∼0.1 μg IgGs in lane 6. The peptides
were visualized with AP-conjugated anti-human (mAb 2F5) and anti-
rabbit (serum, gp41-speciﬁc antibodies) antibodies.
Competition ELISA
A 96-well plate (immunosorb, Nunc) was coated with 50 μl of HA-
gp41 at a concentration of 2 μg/ml in PBS overnight at 4 °C. Excess HA-
gp41 was washed three times with PBS-Tween (0.02%) and the wells
were blocked with 100 μl of 4% BSA in PBS-Tween for 1 h at room
temperature. After a pre-incubation of 1:1 (v/v) mixtures of 50 μl
rabbit serum (at serial dilutions of 1, 2, 4, 8, 16 and 32) and 50 μl
biotinylated antibodies 2F5 or 4E10 at concentrations of 5 ng/ml for
30 min, the wells were washed three times with PBS-Tween and then
incubated with the serum/antibody mixtures for 30 min at room
temperature. The wells were washed three times and incubated with
50 μl of streptavidin–HRP (1:1000) for 1 h at room temperature.
Excess streptavidin was washed ﬁve times and the wells were
incubated with 50 μl POD solution for 10 min. The reaction was
stopped by adding 50 μl 0.2 M H2SO4 and the absorptionwas recorded
at 490 nm.
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